Notice: This company has been marked as potentially delisted and may not be actively trading. Tocagen (TOCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends TOCA vs. MNKD, DVAX, GLPG, ARQT, INDV, AKRO, DYN, EVO, TVTX, and GPCRShould you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include MannKind (MNKD), Dynavax Technologies (DVAX), Galapagos (GLPG), Arcutis Biotherapeutics (ARQT), Indivior (INDV), Akero Therapeutics (AKRO), Dyne Therapeutics (DYN), Evotec (EVO), Travere Therapeutics (TVTX), and Structure Therapeutics (GPCR). These companies are all part of the "medical" sector. Tocagen vs. MannKind Dynavax Technologies Galapagos Arcutis Biotherapeutics Indivior Akero Therapeutics Dyne Therapeutics Evotec Travere Therapeutics Structure Therapeutics MannKind (NASDAQ:MNKD) and Tocagen (NASDAQ:TOCA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, community ranking, earnings, dividends, analyst recommendations, valuation and media sentiment. Is MNKD or TOCA more profitable? MannKind has a net margin of 8.07% compared to Tocagen's net margin of -176,433.34%. MannKind's return on equity of -17.74% beat Tocagen's return on equity.Company Net Margins Return on Equity Return on Assets MannKind8.07% -17.74% 8.68% Tocagen -176,433.34%-327.74%-111.87% Do analysts rate MNKD or TOCA? MannKind presently has a consensus price target of $9.07, indicating a potential upside of 50.19%. Given MannKind's stronger consensus rating and higher possible upside, equities research analysts plainly believe MannKind is more favorable than Tocagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MannKind 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Tocagen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings and valuation, MNKD or TOCA? MannKind has higher revenue and earnings than Tocagen. Tocagen is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannKind$198.96M8.37-$11.94M$0.0786.29Tocagen$40K9,328.41-$63.52M-$2.69-5.80 Does the MarketBeat Community prefer MNKD or TOCA? MannKind received 339 more outperform votes than Tocagen when rated by MarketBeat users. However, 66.03% of users gave Tocagen an outperform vote while only 60.12% of users gave MannKind an outperform vote. CompanyUnderperformOutperformMannKindOutperform Votes58260.12% Underperform Votes38639.88% TocagenOutperform Votes24366.03% Underperform Votes12533.97% Does the media prefer MNKD or TOCA? In the previous week, MannKind had 3 more articles in the media than Tocagen. MarketBeat recorded 3 mentions for MannKind and 0 mentions for Tocagen. MannKind's average media sentiment score of 0.28 beat Tocagen's score of 0.00 indicating that MannKind is being referred to more favorably in the media. Company Overall Sentiment MannKind Neutral Tocagen Neutral Do insiders & institutionals believe in MNKD or TOCA? 49.6% of MannKind shares are held by institutional investors. Comparatively, 21.4% of Tocagen shares are held by institutional investors. 3.0% of MannKind shares are held by company insiders. Comparatively, 10.9% of Tocagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, MNKD or TOCA? MannKind has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Tocagen has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. SummaryMannKind beats Tocagen on 16 of the 19 factors compared between the two stocks. Get Tocagen News Delivered to You Automatically Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TOCA vs. The Competition Export to ExcelMetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$373.14M$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E Ratio-6.5810.0188.8317.53Price / Sales9,328.41335.611,282.2680.28Price / CashN/A22.6336.6032.90Price / Book34.675.084.964.69Net Income-$63.52M$154.90M$117.89M$224.57M Tocagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TOCATocagenN/A$15.60-1.3%N/A+2,138.8%$373.14M$40,000.00-6.5877MNKDMannKind3.6375 of 5 stars$6.13+0.7%$9.07+48.0%+78.9%$1.69B$267.20M87.57400DVAXDynavax Technologies4.5538 of 5 stars$12.48-1.2%$22.00+76.3%-10.8%$1.64B$260.81M96.01350GLPGGalapagos1.364 of 5 stars$24.24-5.5%$30.75+26.9%-36.9%$1.60B$260.09M0.001,123News CoverageARQTArcutis Biotherapeutics2.1617 of 5 stars$13.63-1.3%$16.60+21.8%+290.2%$1.60B$138.71M-7.61150Gap UpINDVIndivior2.4558 of 5 stars$11.51-2.9%$16.00+39.0%-26.9%$1.59B$1.18B-287.681,164Short Interest ↑News CoveragePositive NewsGap UpAKROAkero Therapeutics3.9442 of 5 stars$22.63-8.9%$46.83+107.0%+14.7%$1.58BN/A-6.0330DYNDyne Therapeutics3.5991 of 5 stars$15.29-3.7%$49.91+226.4%-9.5%$1.56BN/A-4.29100News CoverageEVOEvotec1.9966 of 5 stars$4.18-4.1%$5.93+41.9%-47.5%$1.48B$777.05M0.004,200Positive NewsTVTXTravere Therapeutics2.1445 of 5 stars$18.59+2.8%$23.67+27.3%+110.2%$1.45B$203.45M-4.09460Analyst RevisionGPCRStructure Therapeutics1.5565 of 5 stars$25.16-0.4%$81.29+223.1%-33.6%$1.44BN/A-34.00136Short Interest ↑ Related Companies and Tools Related Companies MannKind Alternatives Dynavax Technologies Alternatives Galapagos Alternatives Arcutis Biotherapeutics Alternatives Indivior Alternatives Akero Therapeutics Alternatives Dyne Therapeutics Alternatives Evotec Alternatives Travere Therapeutics Alternatives Structure Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TOCA) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tocagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TOCA Stock Alerts